loading
C 4 Therapeutics Inc stock is traded at $2.66, with a volume of 482.98K. It is down -2.56% in the last 24 hours and up +18.75% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.73
Open:
$2.74
24h Volume:
482.98K
Relative Volume:
0.34
Market Cap:
$189.31M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.9963
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
-2.21%
1M Performance:
+18.75%
6M Performance:
+21.46%
1Y Performance:
-58.50%
1-Day Range:
Value
$2.645
$2.74
1-Week Range:
Value
$2.57
$2.75
52-Week Range:
Value
$1.085
$7.22

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name
Name
C 4 Therapeutics Inc
Name
Phone
(617) 231-0700
Name
Address
490 ARSENAL WAY, WATERTOWN
Name
Employee
110
Name
Twitter
Name
Next Earnings Date
2025-02-24
Name
Latest SEC Filings
Name
CCCC's Discussions on Twitter

Compare CCCC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CCCC
C 4 Therapeutics Inc
2.66 187.89M 20.76M -132.49M -108.55M -2.67
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
394.53 99.62B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
465.89 61.52B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.00 58.91B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ARGX
Argen X Se Adr
756.38 46.69B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
324.34 34.54B 3.81B -644.79M -669.77M -6.24

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-04-25 Initiated Guggenheim Buy
Dec-19-24 Upgrade Wells Fargo Equal Weight → Overweight
Nov-18-24 Initiated Stephens Equal-Weight
Jan-29-24 Upgrade JP Morgan Underweight → Neutral
Dec-13-23 Upgrade Stifel Hold → Buy
Feb-24-23 Upgrade Credit Suisse Underperform → Neutral
Feb-24-23 Downgrade JP Morgan Neutral → Underweight
Nov-04-22 Downgrade JP Morgan Overweight → Neutral
Oct-11-22 Initiated Morgan Stanley Underweight
Apr-28-22 Initiated Credit Suisse Underperform
Apr-11-22 Downgrade BofA Securities Buy → Neutral
Mar-10-22 Initiated JP Morgan Overweight
Feb-11-22 Resumed BMO Capital Markets Outperform
Feb-10-22 Initiated Wells Fargo Equal Weight
Nov-23-21 Initiated BofA Securities Buy
Oct-14-21 Initiated SVB Leerink Mkt Perform
Sep-30-21 Initiated Stifel Hold
Jun-04-21 Initiated H.C. Wainwright Buy
Mar-31-21 Initiated BMO Capital Markets Outperform
Oct-28-20 Initiated UBS Buy
Oct-27-20 Initiated BMO Capital Markets Outperform
Oct-27-20 Initiated Jefferies Buy
View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

pulisher
Sep 12, 2025

Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener

Sep 12, 2025
pulisher
Sep 12, 2025

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Sep 12, 2025
pulisher
Sep 11, 2025

Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Sep 11, 2025
pulisher
Sep 11, 2025

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 11, 2025
pulisher
Sep 11, 2025

192,424 Shares in C4 Therapeutics, Inc. $CCCC Bought by Nuveen LLC - MarketBeat

Sep 11, 2025
pulisher
Sep 10, 2025

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 10, 2025 - BioSpace

Sep 10, 2025
pulisher
Sep 10, 2025

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 10, 2025
pulisher
Sep 10, 2025

Market reaction to C4 Therapeutics Inc.’s recent newsMarket Performance Summary & Accurate Trade Setup Notifications - Newser

Sep 10, 2025
pulisher
Sep 09, 2025

C4 Therapeutics Inc. Included in Top Momentum ScanJuly 2025 Sentiment & Weekly High Return Stock Opportunities - beatles.ru

Sep 09, 2025
pulisher
Sep 09, 2025

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $8.00 Consensus Target Price from Brokerages - MarketBeat

Sep 09, 2025
pulisher
Sep 08, 2025

C4 Therapeutics Inc. Breakout Confirmed by Volume MetricsQuarterly Profit Review & Community Verified Trade Signals - beatles.ru

Sep 08, 2025
pulisher
Sep 08, 2025

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 08, 2025
pulisher
Sep 06, 2025

Is C4 Therapeutics Inc. forming a bottoming baseDollar Strength & AI Enhanced Execution Alerts - Newser

Sep 06, 2025
pulisher
Sep 06, 2025

Can C4 Therapeutics Inc. recover in the next quarterEarnings Recap Summary & AI Driven Stock Movement Reports - Newser

Sep 06, 2025
pulisher
Sep 06, 2025

Historical volatility pattern of C4 Therapeutics Inc. visualizedJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser

Sep 06, 2025
pulisher
Sep 06, 2025

Machine Learning Models Forecast C4 Therapeutics Inc. UptickPortfolio Growth Summary & Daily Stock Momentum Reports - beatles.ru

Sep 06, 2025
pulisher
Sep 06, 2025

Will C4 Therapeutics Inc. benefit from seasonalityWeekly Trading Summary & Daily Volume Surge Signals - خودرو بانک

Sep 06, 2025
pulisher
Sep 06, 2025

What is C4 Therapeutics Inc.’s book value per shareEarnings Recap Report & Precise Trade Entry Recommendations - خودرو بانک

Sep 06, 2025
pulisher
Sep 05, 2025

What is the dividend yield of C4 Therapeutics Inc.July 2025 Summary & Safe Entry Point Identification - خودرو بانک

Sep 05, 2025
pulisher
Sep 05, 2025

Can C4 Therapeutics Inc. sustain its profitability2025 Trading Volume Trends & Verified Stock Trade Ideas - خودرو بانک

Sep 05, 2025
pulisher
Sep 05, 2025

Can C4 Therapeutics Inc. weather a recessionQuarterly Risk Review & Weekly High Return Forecasts - خودرو بانک

Sep 05, 2025
pulisher
Sep 05, 2025

Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener

Sep 05, 2025
pulisher
Sep 05, 2025

Oric Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Sep 05, 2025
pulisher
Sep 05, 2025

Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Sep 05, 2025
pulisher
Sep 05, 2025

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 05, 2025
pulisher
Sep 05, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 05, 2025
pulisher
Sep 05, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Sep 05, 2025
pulisher
Sep 05, 2025

Biogen’s IND for BIIB-142 accepted by FDA - BioWorld MedTech

Sep 05, 2025
pulisher
Sep 05, 2025

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 05, 2025
pulisher
Sep 05, 2025

C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33% - simplywall.st

Sep 05, 2025
pulisher
Sep 05, 2025

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 05, 2025
pulisher
Sep 05, 2025

Chart overlay techniques for tracking C4 Therapeutics Inc.Trade Volume Report & Short-Term Trading Opportunity Alerts - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

Real time breakdown of C4 Therapeutics Inc. stock performanceQuarterly Market Review & Verified Technical Trade Signals - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

Visual trend scoring systems applied to C4 Therapeutics Inc.July 2025 Sector Moves & Growth Focused Entry Reports - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

How to integrate C4 Therapeutics Inc. into portfolio analysis toolsJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser

Sep 05, 2025
pulisher
Sep 04, 2025

Does C4 Therapeutics Inc. show high probability of reboundJuly 2025 Levels & Accurate Intraday Trading Signals - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Building trade automation scripts for C4 Therapeutics Inc.2025 Performance Recap & Comprehensive Market Scan Insights - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 04, 2025
pulisher
Sep 04, 2025

Biogen Inc. shares fall 2.38% intraday as C4 Therapeutics highlights recent achievements in Biogen. - AInvest

Sep 04, 2025
pulisher
Sep 04, 2025

C4 Therapeutics (CCCC) Receives Buy Rating from Guggenheim | CCC - GuruFocus

Sep 04, 2025
pulisher
Sep 04, 2025

Why is C4 Therapeutics Inc. stock going downJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - خودرو بانک

Sep 04, 2025
pulisher
Sep 04, 2025

C4 Therapeutics shares rise 1.95% premarket after Biogen's IND application for IRAK4 degrader accepted by FDA. - AInvest

Sep 04, 2025
pulisher
Sep 04, 2025

Biogen's IND Application Accepted by FDA for C4 Therapeutics' Treatment of Autoimmune Diseases - AInvest

Sep 04, 2025
pulisher
Sep 04, 2025

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - GlobeNewswire

Sep 04, 2025
pulisher
Sep 04, 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Sep 04, 2025
pulisher
Sep 04, 2025

C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

What the charts say about C4 Therapeutics Inc. todayJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 - BioSpace

Sep 04, 2025
pulisher
Sep 03, 2025

How hedge fund analytics apply to C4 Therapeutics Inc. stockStop Loss & Short-Term High Return Strategies - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 03, 2025
pulisher
Sep 03, 2025

Astria Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener

Sep 03, 2025

C 4 Therapeutics Inc Stock (CCCC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.36
price down icon 0.93%
$83.10
price down icon 3.56%
$27.82
price down icon 2.76%
$96.74
price down icon 7.26%
$145.93
price up icon 0.10%
biotechnology ONC
$324.34
price down icon 3.38%
Cap:     |  Volume (24h):